Bioventix plc
(“Bioventix” or the “Company”)
Posting of Annual
Report and Notice of AGM
Bioventix plc (BVXP), a UK company specialising in the
development and commercial supply of high-affinity monoclonal
antibodies for applications in clinical diagnostics, and
development company confirms that its Annual Report and Accounts
for the year ended 30 June 2020 and
the Notice of Annual General Meeting (“AGM”) has been posted to
shareholders.
These documents are available on the Company's website at
www.bioventix.com.
The AGM will be held electronically at 2.00 p.m. on 10 December
2020.
As a result of the current UK Government guidance on social
distancing and prohibiting public gathering over certain numbers,
the Company has taken the decision that this year unfortunately it
will not be possible for shareholders to attend the AGM.
Details on how shareholders can vote by proxy are set out in the
Notice of Annual General Meeting. The Company therefore requests
that shareholders appoint the Chairman of the meeting as a proxy
and provide their voting responses in advance of the AGM.
For further information please
contact:
Bioventix
plc
Peter Harrison |
Chief Executive Officer |
Tel: 01252 728 001 |
|
|
|
finnCap Ltd
Geoff Nash/Simon Hicks
Alice Lane |
Corporate Finance
ECM |
Tel: 020 7220 0500 |
About Bioventix plc:
Bioventix (www.bioventix.com) specialises in the development and
commercial supply of high-affinity monoclonal antibodies with a
primary focus on their application in clinical diagnostics, such as
in automated immunoassays used in blood testing. The antibodies
created at Bioventix are generated in sheep and are of particular
benefit where the target is present at low concentration and where
conventional monoclonal or polyclonal antibodies have failed to
produce a suitable reagent. Bioventix currently offers a portfolio
of antibodies to customers for both commercial use and R&D
purposes, for the diagnosis or monitoring of a broad range of
conditions, including heart disease, cancer, fertility, thyroid
function and drug abuse. Bioventix currently supplies antibody
products and services to the majority of multinational clinical
diagnostics companies. Bioventix is based in Farnham, UK and its
shares are traded on AIM under the symbol BVXP.